Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH-Reference-Cited by-同舟云学术

Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH

Published:2015-10-12 Issue:11 Volume:13 Page:2119-2126
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Kaatz S.¹,Ahmad D.²,Spyropoulos A. C.³⁴,Schulman S.⁵,

Affiliation:

1. Department of Medicine; Hurley Medical Center; Flint MI USA

2. Division of Hematology and Oncology; Department of Medicine; Michigan State University; East Lansing MI USA

3. Anticoagulation and Clinical Thrombosis Services; North Shore-LIJ Health System; Manhasset NY USA

4. Department of Medicine; Hofstra North Shore-LIJ School of Medicine; Manhasset NY USA

5. Department of Medicine; Thrombosis Service; Thrombosis and Atherosclerosis Research Institute; McMaster University; Hamilton ON Canada

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.13140/fullpdf

Reference22 articles.

1. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients;Schulman;J Thromb Haemost,2005

2. (CHMP) CfMPfHU Guideline on clinical investigation of medicinal products for prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation European Medicines Agency 2013

3. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium;Mehran;Circulation,2011

4. The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators;Lancaster;Arch Intern Med,1991

5. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis;Gould;Ann Intern Med,1999

Cited by 994 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prophylactic Dose of Rivaroxaban Versus Warfarin for the Treatment of Isolated Calf Muscle Vein Thrombosis: A Retrospective Propensity Score-Matched Analysis;Annals of Vascular Surgery;2024-11

2. Efficacy and safety of intra-operative thromboprophylaxis with low-molecular-weight-heparin or heparin in patients undergoing surgical resection of colorectal cancer: A post-hoc analysis of the PERIOP-01 trial;Thrombosis Research;2024-10

3. Anticoagulation for the treatment of immune checkpoint inhibitor–associated venous thromboembolism;Blood Advances;2024-09-24

4. Real-World Use and Outcomes of Apixaban for Early Post-Surgical Fontan Thromboprophylaxis;Pediatric Cardiology;2024-09-12

5. A Dynamic, D-dimer-based Thromboprophylaxis Strategy in Patients with COVID-19;F1000Research;2024-09-04